Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 16Recurrence 2Smoldering Multiple Myeloma 1Neuroblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Ganglioneuroblastoma 1

Interventions

daratumumab 4Lenalidomide 3dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Dexamethasone 2Curcumin 2Calcium Dobesilate 2piperine 1isatuximab 1iberdomide 1Watchful Waiting 1Stem Cell Transplantation 1Peripheral Blood Stem Cell Transplantation 1Observation 1Melphalan 1Leflunomide 1IPH-2101 1Dietary Fiber 1Diet, Mediterranean 1Cholestyramine Resin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Smoldering Multiple Myeloma × iberdomide × 90 days × Clear all
NCT04776395 2026-06-01

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

Emory University

Phase 2 Recruiting
68 enrolled
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡